Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck & Co.
Fierce Pharma
ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS
Combining the TROP2 ADC with Keytruda cut the risk of progression or death by 65% versus Keytruda alone in first-line, PD-L1-positive NSCLC.
Angus Liu
May 21, 2026 5:00pm
Merck inks Keytruda supply pact to support Exelixis cancer trial
May 19, 2026 9:38am
From R&D to M&A: Big Pharmas showcase ‘measurable impact’ of AI
May 7, 2026 9:10am
Fierce Pharma
Merck's Welireg surprisingly fails in first-line kidney cancer
Apr 21, 2026 10:00am
AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC
Apr 17, 2026 3:00pm
Merck enlists antibody hunter Infinimmune for $838M biobucks
Mar 31, 2026 8:00am
